IMBiotechnologies Ltd. Expands Approval for Ekobi Embolization Microspheres to Include Treatment of Uterine Fibroids

Press Release: IMBiotechnologies Ltd. Expands Approval for EkobiTM Embolization Microspheres to Include Treatment of Uterine Fibroids
Ekobi Embolization Microspheres, a novel embolization medical device has received Health Canada approval for the treatment of uterine fibroids, a significant women’s health issue.
Edmonton, Canada – November 5, 2019 – IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has received approval from Heath Canada to expand the indications of its lead product, EkobiTM Embolization Microspheres (“Ekobi”), to include treatment of uterine fibroids. Uterine fibroids are a significant women’s health issue; by the age of 50, 70% of women will develop uterine fibroids; up to 50% of uterine fibroids are
symptomatic requiring treatment. Symptoms include abnormal uterine bleeding, pelvic
pressure and pain, infertility, recurrent pregnancy loss, and a significant reduction in a
woman’s quality of life. Ekobi is a patented “first-in-class” embolic therapeutic medical
device that provides women with an alternative to traditional surgical treatments, such as hysterectomy (removal of the uterus) or myomectomy (removal of part of the uterus). “Uterine fibroids can have a major impact on a woman’s physical and social activities,”
said Michael Stewart, CEO of IMB. “We are pleased to offer physicians a biodegradable and non-surgical treatment option for symptomatic uterine fibroids.” Clinical studies have
established safety and efficacy of EkobiTM microspheres and with this approval, EkobiTM microspheres are now indicated for the treatment of hypervascularized tumors, uterine
fibroids and enlarged prostates caused by benign prostatic hyperplasia (“BPH”). Using a minimally invasive technique called embolotherapy, EkobiTM microspheres selectively
block the blood vessels that feed a target tissue, starving it of oxygen and nutrients. An
important advantage of Ekobi is that after providing a therapeutic benefit, EkobiTM
microspheres biodegrade and are completely eliminated from the body. In addition,
Ekobi can be easily seen in the body using minimally invasive ultrasound. Ekobi is the
first, and only, biodegradable embolic agent detectable by ultrasound. EkobiTM Embolization Microspheres has also received US FDA clearance for the treatment of
unresectable/inoperable hypervascularized tumors.
About EkobiTM Embolization Microspheres
Ekobi is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It
is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors. In Canada, it is a class IV medical device approved for the treatment of hypervascularized tumors, uterine fibroids and enlarged prostates due to BPH.
About Embolotherapy
mbolotherapy works by reducing or eliminating the blood supply to target tissues. The
procedure is performed by injecting embolic agents through a catheter into the blood
vessels that feed a target tissue. By selectively blocking the tissue’s blood supply, the
target tissue is either destroyed or devitalized, resulting in therapeutic benefit. About IMBiotechnologies Ltd.

IMBiotechnologies Ltd. is a privately held Canadian medical device company located in
Edmonton, Alberta, focused on the commercialization of medical products in the area of embolotherapy. This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and
uncertainties that could cause actual results to differ materially from those contemplated
by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared,
but cautions that these assumptions regarding the future events, many of which are
beyond the control of the Company, may ultimately prove to be incorrect. The Company
disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information or future events and except as required by law.
For More Information Please Contact: Kelly Mottet
Director of Marketing and Business Development
(780) 233-4294